Biopharmaceutical News: Breaking Biopharmaceutical News, Comments and Articles.

China Biologic Comments on the Proposed Shanghai RAAS Transaction

BEIJING, May 24, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has recently learned from a public announcement issued by Shanghai RAAS Blood Products Co., Ltd. ("Shanghai RAAS"), a public company listed on Shenzhen St...

Sinovac Beijing receives GMP certificate for its proprietary vaccines

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (G...

Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines

BEIJING, May 24, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vacci...

3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement

SHENYANG, CHINA, May 24, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that, at an extraordinary general meeting held today (the "EGM"), the Company's shareholders voted in favor of the proposal to authorize and approve...

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral th...

Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland

WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM).  Vanda was honored at the TCM's 25th Annual Tech Awards Celebration held in Bethesda, Maryland.  The Tech Awards Celebration recognizes the leaders and innovators in the...

Anacor Pharmaceuticals to Present at Deutsche Bank’s 38th Annual Healthcare Conference

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at Deutsche Bank’s 38th Annual Healthcare Conference on Thursday, May 30, 2013 at 2:10 p.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under “Events and Presentatio...

Cubist to Present at Jefferies 2013 Global Healthcare Conference

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Mike Bonney, Cubist’s CEO, will present at Jefferies 2013 Global Healthcare Conference on Monday, June 3, to discuss the company’s business activities, financial outlook, and current news. The conference will be held at Grand Hyatt New York hotel in New York City on Monday...

Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 38th Annual dbAccess Health Care Conference on Wednesday, May 29, 2013, at 8:40 a.m. EDT (1:40 p.m. BST) from The Westin Boston Waterfront Hotel. The presentation may be accessed under the Investors tab on www.alkermes.com and will b...

Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference

SAN DIEGO, May 23, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 38th Annual dbAccess Health Care Conference in Boston.   The live presentation takes place on Thursday, May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time.&...

New showcase for Malvern Instruments’ extensive range of GPC/SEC systems and detectors

23 May 2013: Malvern, UK. New pages on the Malvern Instruments website provide information that enables scientists to make informed choices about detector configurations for their specific GPC/SEC applications.  Showcasing the company’s comprehensive range of Viscotek systems and detectors for gel permeation/size exclusion chromatography (GPC/SEC) these pages help analysts to ident...

Zensun Announces Positive Clinical Results for Neucardin(TM) to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients

SAN DIEGO and SHANGHAI, May 23, 2013 /PRNewswire/ -- Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun's in...

Lightlake Therapeutics’ Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting

̶ Binge Eating Disorder Added to DSM-5 ̶̶ Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company”, “We” or “Lightlake”), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company’s Phase II clinical trial of its nasal spray treatment for Binge...

CytRx to Present at the Marcum MicroCap Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A. Kriegsman will present at the 2nd Annual Marcum MicroCap Conference on Thursday, May 30, 2013, at 10:00 a.m. Eastern time (7:00 a.m. Pacific time). The conference is being held at the Grand Hyatt...

miRagen Therapeutics Achieves First Milestone in Strategic Alliance with Servier

Servier selects third cardiovascular target triggering the first milestone under the collaboration Servier, a privately-run French research-based pharmaceutical company and a major player in Europe and emerging markets having expertise in the development of treatments for cardiovascular diseases, and miRagen Therapeutics, Inc., a biopharmaceutical comp...

Soligenix' ThermoVax technology receives US patent

Clinical stage biopharmaceutical company Soligenix has received US patent for the vaccine thermostabilization technology, ThermoVax.

Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients

MILFORD, Mass., May 23, 2013 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy for the treatment of HCV infection. This study will be conducted in healthy, HCV-infected...

The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments

EXTON, Pa., May 23, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, unaided, one in five surveyed gastroenterologists, hepatologists, and infectious disease specialists reported that in the past six months, they have begun warehousing patients (e.g., intentionally delaying treatment) in anti...

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating...

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focu...

Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer

SAN DIEGO, May 23, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of David A. Ramsay as Chief Financial Officer.  Mr. Ramsay was most recently Vice President, Corporate Development at Halozyme.  (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)     "With his established financial management experience an...

Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference

NEW YORK, May 23, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present at the Deut...

Zensun Announces Positive Clinical Results for Neucardin™ to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients

SAN DIEGO and SHANGHAI, May 23, 2013 /PRNewswire/ -- Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun's in...

Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)

ATLANTA, May 23, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease treatments, announced today that it will present new results on its antiviral program to 'prevent' PML at an industry conference sponsored by the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, Roche and Biogen Idec).  JC polyomavirus (JCV) is the causative agent of Pr...

Tecan appoints Dr. Klaus Lun to the Management Board

Tecan Group AG / Tecan appoints Dr. Klaus Lun to the Management Board . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Männedorf, Switzerland, May 23, 2013 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that Dr. Klaus Lun has been appointed Head of Corporate Development and a member of the Management Board. He...